A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation

Ole Rogeberga,⁎, Daniel Bergsvikb, Lawrence D. Phillipsc, Jan van Amstermanda, Niamh Eastwoodd, Graeme Hendersonf, Micheal Lynskeyg, Fiona Meashamh, Rhys Pontonl, Steve Rollesj, Anne Katrin Slagk, Polly Taylork, David Nuttl

a Ragnar Frisch Centre for Economic Research, Norway
b Norwegian Institute of Public Health, Norway
c London School of Economics and Political Science, United Kingdom
d Academic Medical Center (AMC), University of Amsterdam, Netherlands
e Release, United Kingdom
f University of Bristol, United Kingdom
g King’s College London, United Kingdom
h Durham University, United Kingdom
i University of Auckland, New Zealand
j Transform Drug Policy Foundation, United Kingdom
k Independent Consultant in Veterinary Anaesthesia, United Kingdom
l Imperial College London, United Kingdom

ARTICLE INFO

Keywords:
Drug policy
Multi-criterion decision analysis
Alcohol
Cannabis

ABSTRACT

Background: Drug policy, whether for legal or illegal substances, is a controversial field that encompasses many complex issues. Policies can have effects on a myriad of outcomes and stakeholders differ in the outcomes they consider and value, while relevant knowledge on policy effects is dispersed across multiple research disciplines making integrated judgements difficult.

Methods: Experts on drug harms, addiction, criminology and drug policy were invited to a decision conference to develop a multi-criterion decision analysis (MCDA) model for appraising alternative regulatory regimes. Participants collectively defined regulatory regimes and identified outcome criteria reflecting ethical and normative concerns. For cannabis and alcohol separately, participants evaluated each regulatory regime on each criterion and weighted the criteria to provide summary scores for comparing different regimes.

Results: Four generic regulatory regimes were defined: absolute prohibition, decriminalisation, state control and free market. Participants also identified 27 relevant criteria which were organised into seven thematically related clusters. State control was the preferred regime for both alcohol and cannabis. The ranking of the regimes was robust to variations in the criterion-specific weights.

Conclusion: The MCDA process allowed the participants to deconstruct complex drug policy issues into a set of simpler judgements that led to consensus about the results.

Introduction

Substance use can cause harms to individuals and societies, but opinions differ regarding how these harms are best reduced. Such opinions will also reflect how we view trade-offs, as policies need to balance the harms of use against negative consequences of restrictive policies and the pleasures and benefits that the majority of users may claim to experience. Over time, and across regions, policies – even for the same substance – have ranged from strict prohibitions criminalising production and consumption to relatively unregulated commercial markets. In recent years, policy changes in US states, Uruguay and Canada have fuelled a growing debate on whether cannabis supply and

⁎ Corresponding author at: Ragnar Frisch Centre for Economic Research, Gaustadalléen 21, 0349 Oslo, Norway.
E-mail addresses: ole.rogeberg@frisch.uio.no (O. Rogeberg), daniel.bergsvik@fhi.no (D. Bergsvik), larry_phillips@mtn.com (L.D. Phillips), jan.van.amsterdam@amc.uva.nl (J. van Amsterdam), niamh@release.org.uk (N. Eastwood), graeme.henderson@bris.ac.uk (G. Henderson), michael.lynskey@kcl.ac.uk (M. Lynskey), f.measham@durham.ac.uk (F. Measham), r.ponton@auckland.ac.nz (R. Ponton), steve@tdpf.org.uk (S. Rolles), anne.schlag@kcl.ac.uk (A.K. Schlag), polly@taylormonroe.co.uk (P. Taylor), d.nutt@imperial.ac.uk (D. Nutt).

https://doi.org/10.1016/j.drugpo.2018.01.019
Received 3 November 2017; Received in revised form 8 January 2018; Accepted 25 January 2018
0955-3959/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).

Please cite this article as: Rogeberg, o., International Journal of Drug Policy (2018), https://doi.org/10.1016/j.drugpo.2018.01.019
consumption should be legalised and, if so, how strictly it should be regulated (Caulkins & Kilmer, 2016; Hawken, Caulkins, Kilmer, & Kleiman, 2013; Room, 2014; Uchtenhagen, 2014). The appropriate balance between “free market” and “government control” also remains an issue for alcohol, with a current example being the debate over minimum unit pricing (Holmes et al., 2014; Stockwell, Auld, Zhao, & Martin, 2012). Public health arguments are frequently emphasised in these discussions (Hall & Degenhardt, 2009; Hall & Lynskey, 2016; Room, Babor, & Rehm, 2005) with a particular focus on adolescent use (Hasin et al., 2015; Simons-Morton, Pickett, Boyce, ter Bogt, & Schkade, Schwarz, & Gregory, 1999). In addition, people’s stated beliefs regarding the effects of different drug policies may themselves serve primarily as expressions of cultural and political identity (Kahan, 2016a, 2016b). As a result, individuals are likely to express policy views that are sensitive to decision-irrelevant factors, and potentially based on false beliefs regarding both the consequences of drug use (benefits, risks and harms) and the likely consequences of drug policy regimes.¹

Structured decision making processes can be thought of as tools developed to help individuals and groups develop “well-constructed preferences.” These are defensible, considered judgments arrived at through a structured, systematic process designed to assist decision-makers in clarifying options and choice criteria, breaking complex judgments down into simpler issues, and helping participants access and integrate relevant information.

This study aimed to develop an analytical framework to describe, assess and discuss different drug regulatory regimes for a Western context (Western Europe and North-America). To do this, we convened a decision conference over two one-and-a-half day sessions to run a multi-criterion decision analysis (MCDA), an established and well-researched decision making process (Phillips, 2007) previously applied to subjects ranging from nuclear waste management (Morton, Airoldi, & Phillips, 2009) to the risk-benefit ratio of prescription drugs (Hughes et al., 2016). Participants were experts on the harms of drugs, addiction, criminology and drug policy. Employing the MCDA process, the participants defined policy options and assessment criteria, and evaluated each policy option on each criterion for different drugs. By combining data and expert judgments to assess real and hypothetical policy states, this new approach can contribute to the literature on comparative policy analysis (Ritter, Livingston, Chalmers, Berends, & Reuter, 2016).

Methods

Study design

Expert participants with varied relevant backgrounds (Panel 1) attended two MCDA sessions (September 10–11th 2015, January 20–21st 2016) to compare alternative drug policies in a Western context. The sessions were facilitated by Lawrence Phillips, an independent specialist in decision analysis modelling, and David Nutt, a medical researcher, and employed decision making software (LSE/Catalyze, 2016) to build, refine and score a model which was projected on a screen in full view of all participants.

Panel 1. Facilitators and participating experts in the drug policy MCDA workshop.

Participants

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dima Abdulrahim</td>
<td>Addiction and Offender Care Directorate, Central and Northwest London NHS Foundation Trust</td>
</tr>
<tr>
<td>Jan van Amsterdam</td>
<td>Amsterdam Academic Medical Center (AMC)</td>
</tr>
<tr>
<td>Roland Archer</td>
<td>Analytical Laboratory, Guernsey (first conference only)</td>
</tr>
<tr>
<td>Daniel Bergsvik</td>
<td>Norwegian Institute of Public Health, Oslo, Norway</td>
</tr>
<tr>
<td>Niannah Eastwood</td>
<td>Executive Director, Release</td>
</tr>
<tr>
<td>Greame Henderson</td>
<td>Professor of Pharmacology, Bristol University</td>
</tr>
<tr>
<td>Tom Lloyd</td>
<td>Independent drugs policy advisor, former Cambridgeshire chief police constable</td>
</tr>
<tr>
<td>Michael Lynskey</td>
<td>Professor of Addictions, National Addictions Centre, King’s College London</td>
</tr>
<tr>
<td>Fiona Measham</td>
<td>Professor of Criminology, Durham University</td>
</tr>
<tr>
<td>Ole Røgeberg</td>
<td>Ragnar Frisch Centre for Economic Research, Oslo, Norway</td>
</tr>
<tr>
<td>Steve Rolles</td>
<td>Senior Policy Analyst, Transform Drug Policy Foundation</td>
</tr>
<tr>
<td>Jeremy Sane</td>
<td>Director for Government Affairs and Communications, Angelus Foundation (first conference only)</td>
</tr>
<tr>
<td>Anne Slag</td>
<td>Senior Researcher, King’s Centre for Risk Management (first conference only)</td>
</tr>
<tr>
<td>Janie Sheridan</td>
<td>Professor, Centre for Addiction Research, University of Auckland, New Zealand</td>
</tr>
<tr>
<td>Polly Taylor</td>
<td>Independent consultant in Veterinary Anaesthesia</td>
</tr>
<tr>
<td>Tim Williams</td>
<td>Consultant addiction psychiatrist, NHS</td>
</tr>
<tr>
<td>Rhys Fonton</td>
<td>School of Pharmacy, University of Auckland, New Zealand (second decision conference only)</td>
</tr>
<tr>
<td>David Nutt</td>
<td>Professor of Neuropsychopharmacology, Imperial College London</td>
</tr>
<tr>
<td>Larry Phillips</td>
<td>Eminent Professor, London School of Economics, and Director, Facilitations Ltd</td>
</tr>
</tbody>
</table>

¹ Arguably, government decision-making suffers from similar issues, with drug policies ignoring established research (Rogeberg, 2015) unless it conforms to implicit and unstated assumptions (MacCoun & Reuter, 2008). Stevens (2011) provides an ethnographic study of how “evidence” is used selectively to support persuasive policy stories in line with unstated ideological principles – see also Stevens and Measham (2014).
دریافت فوری
متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات